(UroToday.com) The 2025 European Society of Medical Oncology (ESMO) Annual Congress held in Berlin, Germany between October ...
Key findings on renal cell carcinoma (RCC) presented at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium include the final results of the CheckMate 9ER and COSMIC-313 ...
There is currently no effective therapy for patients with advanced HLRCC-associated papillary renal cell carcinoma. Treatment with bevacizumab and erlotinib resulted in a confirmed response of 72% in ...
Dr. Alexander Decruyenaere presented the poster Optimal treatment duration in metastatic renal cell carcinoma patients responding to immune checkpoint inhibitors: should we treat beyond two years? Dr.
Fumarate hydratase-deficient renal cell carcinoma is a rare and aggressive kidney cancer, and treatment guidance has been unclear. In this nonrandomized trial, the objective response rate was 56% with ...
A phase 2 trial supports SBRT for primary treatment of localized RCC. Stereotactic body radiotherapy (SBRT) showed favorable long-term local control and cause-specific survival (CSS) in a phase 2 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback